Beta Bionics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 57% revenue growth to $27.6M, with gross margin expanding to 59.5% and strong pharmacy channel traction. Full-year guidance was raised for revenue, gross margin, and pharmacy mix, while cash reserves remain robust and R&D investments accelerate.
-
The session highlighted the automation and ease-of-use of the iLet insulin pump, its differentiated business model, and plans for significant sales force expansion. The Mint patch pump is set for late 2027, and a bi-hormonal pump is in phase II trials, aiming to further disrupt the market.
Fiscal Year 2025
-
Delivered 54% year-over-year revenue growth in 2025, driven by strong iLet adoption and pharmacy channel expansion. Guidance for 2026 anticipates continued growth, with increased investment in sales, R&D, and the Mint patch pump, while addressing FDA quality concerns.
-
Strong Q3 adoption driven by product simplicity and robust clinical outcomes, with significant growth in the pharmacy channel and a focus on rapid, focused product development. The company targets faster-than-industry profitability and is preparing for a major patch pump launch by 2027.
-
Revenue and patient starts are accelerating, driven by pharmacy reimbursement and ease of use. Patch pump development is on track for a 2027 launch, with a focus on patient-friendly design and pharmacy-only reimbursement. Regulatory remediation is progressing smoothly.
-
Q3 net sales grew 63% year-over-year to $27.3M, with gross margin up to 55.5% and record new patient starts. Full-year revenue and margin guidance were raised, driven by strong pharmacy channel growth and high retention. FDA reporting remediation is underway, with no impact on product performance.
-
The conference highlighted advances in automated insulin delivery, emphasizing adaptive algorithms, user simplicity, and a multi-form factor strategy. Rapid innovation, a pay-as-you-go model, and exclusive bihormonal technology position the company for growth in both type 1 and type 2 diabetes markets.
-
Product adoption and pharmacy channel growth are driving strong financial performance, with raised revenue guidance and expanding market share, especially in type 2 diabetes. The Mint patch pump is on track for a 2027 launch, and the company is focused on pharmacy reimbursement and efficient operations.
-
Q2 2025 net sales grew 54% year-over-year to $23.2 million, with strong iLet adoption and pharmacy channel expansion. Full-year guidance for net sales and gross margin was raised, and innovation pipeline milestones remain on track.
-
Bionic Portal and Mint patch pump were introduced to enhance provider access and user experience, with Mint targeting a 2027 launch and pharmacy channel expansion. iLet’s adaptive algorithm delivers strong glycemic outcomes across diverse populations, and the pharmacy model is expected to drive long-term profitability.
-
Q1 saw a 9% revenue beat and strong new patient growth, driven by pharmacy channel adoption and new product launches. Revenue and gross margin guidance were raised, with pharmacy mix and type 2 patient adoption increasing. Patch pump commercialization is targeted for end of 2027.
-
Q1 2025 net sales grew 36% year-over-year to $17.6 million, with strong new patient starts and increased pharmacy channel adoption. Guidance for 2025 was raised across revenue, gross margin, and pharmacy mix, reflecting confidence in continued growth and operational leverage.
Fiscal Year 2024
-
Net sales grew 443% year-over-year to $65.1M in 2024, driven by rapid iLet adoption and expanded pharmacy channel access. 2025 guidance projects $80–$85M revenue, with over 20% of new starts via pharmacy and continued investment in innovation and pipeline programs.